Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice

Molecular Cancer Therapeutics

Volumn 7, Issue 5, 2008, Pages 1329-1335

  Bian, Tao ^a   Wang, Yue ^a,c   Lu, Zhenhua ^a   Ye, Zhenmei ^a   Zhao, Li ^a   Ren, Jiao ^a   Zhang, Hui ^a   Ruan, Li ^a   Tian, Houwen ^a,b  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Biotech Center for Viral Disease Emergency   (China)

^c Division of Hepatitis   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHIMERIC PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN E7; PROTEIN L1E7; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; WART VIRUS VACCINE; CAPSID PROTEIN; EPITOPE; HPV16 L1E7 CHIMERIC VIRUS LIKE PARTICLE; HPV16 L1E7 CHIMERIC VIRUS-LIKE PARTICLE; HYBRID PROTEIN; L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; C57BL 6 MOUSE; CANCER IMMUNIZATION; CANCER PREVENTION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; EMBRYO; ESCHERICHIA COLI; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; LUNG TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PURIFICATION; PROTEIN RENATURATION; TUMOR IMMUNITY; TUMOR REJECTION; VIRUS INFECTION; VIRUS LIKE AGENT; ANIMAL; C57BL MOUSE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM;

ANIMALS; CAPSID PROTEINS; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, FUSION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; TUMOR VIRUS INFECTIONS;

EID: 49849092724     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2015     Document Type: Article

References (36)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
2. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24 Suppl 3:S11-25.
3. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries - key challenges and issues. N Engl J Med 2007;356:1908-10.
4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
5. Favre M, Ramoz N, Orth G. Human papillomaviruses: general features. Clin Dermatol 1997;15:181-98.
6. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11-22.
7. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
8. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002;2:59-65.
9. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004;4:46-54.
10. Schwarz E. Structure and transcription of human papillomavirus type 18 and 16 sequence in cervical carcinoma cells. Nature 1985;314:111-4.
11. U.S. Food and Drug Administration: FDA briefing information on HPV vaccine. Rockville (MD): Vaccines and Related Biological Products Advisory Committee; 2006.
12. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-702.
13. Tomson TT, Roden RB, Wu TC. Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr Opin Investig Drugs 2004;5:1247-61.
14. Brinkman JA, Hughes SH, Stone P, et al. Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 2007;23:337-52.
15. Newall AT, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007;7:289-96.
16. Chan JK, Berek JS. Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 2007;25:2975-82.
17. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
18. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
19. Miyahira Y, Murata K, Rodriguez D, et al. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 1995;181:45-54.
20. Ohlschlager P, Osen W, Dell K, et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 2003;77:4635-45.
21. Roden RB, Hubbert NL, Kirnbauer R, Breitburd F, Lowy DR, Schiller JT. Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol 1995;69:5147-51.
22. Muller M, Zhou J, Reed TD, et al. Chimeric papillomavirus-like particles. Virology 1997;234:93-111.
23. Schiller JT, Lowy DR. Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opin Biol Ther 2001;1:571-81.
24. Schiller JT, Lowy DR. Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 2001;28:50-4.
25. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 2000;5:557-67.
26. Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol 1998;72:6151-4.
27. Yuan H, Estes PA, Chen Y, et al. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol 2001;75:7848-53.
28. Panda AK. Bioprocessing of therapeutic proteins fromthe inclusion bodies of Escherichia coli . Adv Biochem Eng Biotechnol 2003;85:43-93.
29. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci U S A 1991;88:110-4.
30. Da Silva DM, Schiller JT, Kast WM. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 2003;21:3219-27.
31. Greenstone HL, Nieland JD, de Visser KE, et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A 1998;95:1800-5.
32. Kadish AS, Timmins P, Wang Y, et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 2002;11:483-8.
33. Boursnell ME, Rutherford E, Hickling JK, et al. Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996;14:1485-94.
34. Li M, Cripe TP, Estes PA, Lyon MK, Rose RC, Garcea RL. Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli : characterization of protein domains involved in DNA binding and capsid assembly. J Virol 1997;71:2988-95.
35. McCarthy MP, White WI, Palmer-Hill F, Koenig S, Suzich JA. Quantitative disassembly and reassembly of human papillomavirus type 11 virus-like particles in vitro. J Virol 1998;72:32-41.
36. Fligge C, Giroglou T, Streeck RE, Sapp M. Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. Virology 2001;283:353-7.